Skip to content

Clinical trials

Kidney Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Kidney Neoplasms Clear all

954 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200030
200125
200224
200323
200429
200527
200640
200741
200837
200933
201025
201122
201229
201317
201431
201519
201628
201739
201831
201933
202044
202130
202239
202345
202442
202560
202639

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed467
Recruiting157
Terminated113
Unknown status94
Active, not recruiting56
Withdrawn33
Not yet recruiting26
Enrolling by invitation5
Suspended2
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)55
Memorial Sloan Kettering Cancer Center35
M.D. Anderson Cancer Center21
Pfizer21
Children's Oncology Group15
Bristol-Myers Squibb12
National Institutes of Health Clinical Center (CC)11
Case Comprehensive Cancer Center10
Novartis Pharmaceuticals10
University Hospital, Bordeaux10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Kidney Neoplasms954
Carcinoma, Renal Cell478
Lung Neoplasms134
Breast Neoplasms125
Prostatic Neoplasms121
Melanoma112
Urinary Bladder Neoplasms108
Neoplasms102
Ovarian Neoplasms101
Colorectal Neoplasms85

Trials

Showing 76 to 100 of 954. Each trial links to its page on Pharma Observatory.

854 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.